Goldman Sachs analyst Andrea Tan raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $51 from $45 and keeps a Neutral rating on the shares.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARS:
- Tarsus Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
- Tarsus Pharmaceuticals: Strong Market Performance and Growth Potential Justify Buy Rating
- Strong Market Position and Growth Potential Drive Buy Rating for Tarsus Pharmaceuticals
- Tarsus Pharmaceuticals Reports Strong Q3 2025 Growth
- Tarsus Pharmaceuticals: Strong Financial Performance and Strategic Growth Justify Buy Rating